One challenge facing biology is the elucidation of the function of the estimated 30 000 human genes and their polymorphic variants. Reagents that affect the activity of specific genes will be useful in the dissection of cellular regulatory networks. Here, as a test case, we used a twobait two-hybrid system to identify peptide aptamers that distinguish allelic forms of H-Ras. Some of these anti-Ras aptamters inhibit the interaction of oncogenic Ras with cRaf1 in vitro, and abolish EGF-stimulated activation of cRaf1 in vivo. These experiments show that the inactivation of protein function by peptide aptamers represents a viable approach to the understanding and control of signaling pathways and oncogenic missense alleles.
Introduction
Genetic analysis is a powerful tool for understanding the regulatory networks that govern biological processes. However, the isolation of specific missense alleles is currently impractical for metazoans such as mammals. Reagents that control gene function will be particularly useful in the analysis of mammalian cellular regulatory networks and for the eventual development of allele-specific therapeutic agents.
Peptide aptamers are generally referred to conformationally constrained peptides of random sequence displayed by an E. coli thioredoxin platform (Colas et al., 1996) or some other platforms (Norman et al., 1999) . Anti-Cdk2 aptamers can inhibit Cdk2 activity in vitro (Colas et al., 1996) , and intracellular expression of these aptamers can retard cell cycle transitions in human cells (Cohen et al., 1998) . Peptide aptamers that inhibit E2F (Fabbrizio et al., 1999) , Drosophila Cdks (Kolonin and Finley, 1998) and the mating pathway in yeast (Geyer et al., 1999) have also been described. We reasoned that peptide aptamers, that specifically bound an activated allelic form of Ras, might inhibit Ras function in vivo by directly disrupting Ras interaction with its effectors.
Ras proteins and related GTPases function as molecular switches in many signal transduction pathways, cycling between their GTP-bound (active) and GDP-bound (inactive) conformational states (Boguski and McCormick, 1993) . One function of Ras proteins is to recruit Raf-1 kinase to the plasma membrane and activate its kinase activity (Leevers et al., 1994; Stokoe et al., 1994; Stokoe and McCormick, 1997) . Allelic variations of Ras, for example, the most common variant, Gly 12 to Val, activate it; such mutationally activated allelic forms of the three human Ras proteins are found in about 30% of human cancers (Barbacid, 1987) .
In this study, we isolate peptide aptamers that distinguish allelic forms of H-Ras using the two-bait two-hybrid system (Xu et al., 1997) . Some of these aptamers inhibit the interaction between Ras and cRaf1 in vitro, and abolish EGF-stimulated activation of c-Raf1 in cultured cells.
Results

Isolation of peptide aptamers that distinguish H-Ras V 12 and H-RasA 15
Ras V 12 is in the GTP-bound form (active) while RasA 15 adopts the GDP-bound form (inactive). To identify peptide aptamers that distinguish these two allele forms in a single step, we used the yeast two-bait two-hybrid system (Xu et al., 1997) . In the system, we used the URA3 reporter with a RasV 12 bait and the LacZ reporter with a RasA 15 bait (Figure 1) . Inclusion of RasA 15 as the second bait helps to identify and eliminate peptide aptamers that interact specifically with the inactive form of Ras. Both baits carried the A 186 mutation to ensure nuclear localization for twohybrid interaction to take place.
From 3.5610 7 peptide aptamers, we selected a pool of about 350 that bound RasV 12 . From the pool, we obtained five peptide aptamers that interacted strongly with RasV 12 as judged by the cell growth rate in an interaction mating assay (Finley and Brent, 1994) . In this study, we used three peptide aptamers newly isolated from this pool: pep9, pep141 and pep2, and two that were isolated previously, pep22 and pep104 (Xu et al., 1997) . As judged by the lacZ phenotype (Figure 2a ), pep9 and pep141 interacted with the active allelic form (RasV 12 A 186 ) but not with the inactive allelic form (RasA 15 A 186 ), while pep22 interacted with both the active and the inactive forms of Ras ( Figure   2a ). These peptide aptamers showed the same specificity on a different, LEU2 reporter gene ( Figure  2c ). The sequences of the aptamers' variable regions are shown in Figure 2d , none of them shows significant sequence similarity to proteins with which Ras normally interacts, or to other known proteins (data not shown).
Peptide aptamers that bind more strongly to RasV 12 than wild-type Ras
To test whether these aptamers might detect epitopes that differ between the activated form of wild-type Ras (RasA 186 ) and mutationally activated Ras, we used an interaction mating assay (Finley and Brent, 1994) to estimate the strength of their interaction with these proteins. In this assay, CWXY2 strains containing an integrated TetOp-URA3 reporter and expressing either RasV 12 A 186 or RasA 15 A 186 (as baits) were mated with RFY206 strains expressing various peptide aptamers (as preys). The diploid yeast were replicated on the galactose or glucose medium supplemented with 5 mg/ ml 6-azaruracil but lacking Leu, Trp and Ura. The plates were incubated at 308C up to 9 days. In doing so, we measured cell growth rate depending on TetOp-URA3 expression in a medium lacking uracil ( Figure  3 ). Both pep141 and pep9 preferred RasV 12 to RasA 186 ; pep141 interacted with both RasV 12 and RasA 186 more strongly than Pep9. By contrast, Pep22, the strongest interactor in this assay, slightly preferred RasV 12 A 186 to RasA 186 although it also bounded to RasA 15 A 186 (Figure 2 ). c-Raf1 did not show any preference towards RasV 12 A 186 and RasA 186 . Although pep104 preferred RasV 12 A 186 , we did not further test pep104 because it was a very weak interactor ( Figure 2 ) and expressed as truncated proteins in mammalian cells (data not shown).
Ras aptamers that block the interaction of RasV 12 with c-Raf1 in vitro
To confirm the interaction of peptide aptamers with RasV 12 in yeast two-hybrid assays, we tested whether some of the anti-Ras aptamers disrupted the RasV 12 / Raf interaction in vitro. Figure 4 shows that both purified recombinant pep141 and pep22 inhibit the interaction of RasV 12 with its effector c-Raf in vitro. Based on two independent assays, the IC 50 's for pep141 and pep22 are 100 nM and 500 nM respectively. Pep2 ( Figure 4a ) did not affect the RasV 12 /Raf interaction under these conditions.
Ras aptamers that inhibit Raf kinase activation in vivo
We further investigated whether these aptamers inhibited Ras function in mammalian cells. To do this, we co-transfected COS cells with constructions that directed the synthesis of Myc-tagged Raf and peptide aptamers fused to GST, and stimulated the cells with hEGF (Luo et al., 1996) . GST fusion of these aptamers facilitated their intracellular expression in COS cells (data not shown). As reported before (Luo et al., 1996) , we assayed the Raf kinase activity by immunoprecipitating Myc-tagged Raf and assaying its kinase activity toward MEK, subsequently MEK activity on its substrate, a kinase-dead variant of Erk2. Figure 4d shows that expression levels of the peptide aptamers in mammalian cells are similar. Pep9, a control peptide aptamer, and thioredoxin itself, had no effect on the Raf kinase activation. By contrast, pep141 and pep22 abolished Raf kinase activation stimulated by EGF, similar to the effect of C4 (Luo et al., 1996) , a Raf fragment containing the ras binding domain. Inhibition by these aptamers was much more potent than that by RasN 17 , a dominant negative allele of Ras active in this assay (Luo et al., 1996) .
Discussion
Ras aptamers specific to the activated allele of Ras Ras alternates between GTP-bound and GDP-bound conformations. Nucleotide exchange factors interact preferentially with the GDP-bound conformation, while a growing list of partners interact specifically with the GTP-bound conformation, including GAP, PI(3) kinase, RalGDS, Rin, Rlf, and c-Raf1 (Katz and McCormick, 1997) . Structural differences between the GTP-bound and GDP-bound conformations are most pronounced in two regions, switch I (residues 30 -38) and switch II (residues 60 -76) (Milburn et al., 1990) . All known partners specific for GTP-Ras interact with an effector region (residues 32 -40) that largely overlaps switch I.
Here, we selected peptide aptamters against two allelic forms of Ras, RasV 12 and RasA 15 , in which the protein is held in different conformation. RasV 12 is in the active conformation and RasA 15 is in the inactive conformation. Pep9 and pep141 interact only with the active RasV 12 variant of Ras, while pep2 interacts with both the active RasV 12 and the inactive RasA 15 variant. In two-hybrid experiments, these aptamers did not interact with RasL 35 R 37 A 186 , a Ras allele defective in the Switch I/effector region (not shown), suggesting that these aptamers interact with the effector region of Ras.
To probe differences between epitopes displayed by RasV 12 and wild-type, we took advantage of the tunable nature of the TetOp-URA3 reporter to carefully compare binding of these aptamers to these proteins. In the yeast nucleus, wild-type Ras appears to prefer the GTP-bound state, as indicated by the fact that Ras and RasV 12 interact equally well with c-Raf1 (Figure 3) . Our experiments showed that pep9, pep104, and pep141 all prefer to interact with RasV 12 than with Ras (Figure 3) , suggesting that these aptamers may recognize an epitope displayed slightly differently by RasV 12 . This idea is consistent with existing data that shows subtle structural differences, at least in the conformation of the switch II region, between truncated (residues 1 -166) wild-type Ras-GppNp and RasV 12 -GppNp complexes (Krengel et al., 1990) . Our results with these artificial aptamer proteins raise the possibility that some of the oncogenicity of RasV 12 my be due to its interaction with a hitherto-unidentified naturally-occurring preferred partner in vivo.
Ras peptide aptamers that block the interaction of oncogenic Ras with its effectors and inhibit EGF-stimulated Raf activation
Pep141, specific to RasV 12 and Ras, inhibited the interaction of RasV 12 with c-Raf1 and with IC 50 of 100 nM. Pep22, which interacted with Ras, RasV 12 and RasA 15 , inhibited the Ras/Raf interaction with IC 50 of 500 nM. (Figures 3 and 4a) . These results prompted us to test whether some of these aptamers could inhibit Ras functions in vivo. Using a transient transfection assay (Luo et al., 1996) , we showed that pep141 and pep22 abolished EGF-stimulated activation of Raf kinase, presumably by competing with Raf for binding to the Ras effector domain. This magnitude of the inhibition of kinase activity was far greater than that caused by RasN 17 , a dominant negative form of Ras (Figure 4 ) even though pep22 interacted with RasV 12 Figure 3 Comparison of the interaction of peptide aptamers with RasV 12 and wild-type Ras in an interaction mating assay. CWXY2 strains containing an integrated TetOp-URA3 reporter and expressing either RasV 12 A 186 or RasA 15 A 186 (as baits) were mated with RFY206 strains expressing various peptide aptamers (as preys). The diploid yeast were replicated on the galactose or glucose medium supplemented with 5 g/ml 6-azauracil but lacking Leu, Trp and Ura. The plates were incubated at 308C for up to 9 days as well as with RasA 15 , it could inhibit Ras signaling very effectively, presumably it is a very strong interactor of Ras as shown in Figure 3 . Although pep9 is specific to the active form of Ras (Figure 2a,b) , it could not inhibit EGF-stimulated activation of Raf kinase, presumably pep9 was a very weak interactor in the mating assays (Figure 3) . Our results thus demonstrate the feasibility of using peptide aptamers to specifically affect the function of allelic or conformational protein variants and their modulators and effectors.
In summary, we used the yeast two-bait two-hybrid to identify peptide aptamers that preferentially recognize epitopes present on mutationally-activated RasV 12 . The two-bait system offers an efficient way to select such rare discriminatory aptamers among rather larger (here, 3.5610 7 ) starting pools. The use of two-bait selections with sufficiently large libraries should allow the isolation of aptamers or natural proteins that recognize allelic variants of other protein targets. Because such aptamers can disrupt the interaction of their target proteins with their effectors, they should be useful as reagents for functional characterization of proteins and their numerous polymorphic variants or alternative splice forms uncovered by genome sequencing efforts (Adams et al., 1995; Lander et al., 2001; Modrek and Lee, 2002; Venter et al., 2001) . Organic compounds that mimic the variable regions of these peptide aptamers may be useful as conformation-and allele-specific therapeutics.
Materials and methods
The two-bait interaction hunt
We cloned H-RasV 12 to the EcoRI/XhoI sites or pCWX200 and H-RasA 15 to the same sites of pEG202. We transformed the yeast strain CWXY2 (MATa, ura3, his3, trp1, leu2, lys2-delta1::TetOp-URA3) (Xu et al., 1997) with pCWX200-RasV 12 , pEG202-RasA 15 and pCWX24, which we subsequently transformed with a peptide aptamer library (Colas et al., 1996) , using the lithium acetate method. We note that the best transforming efficiency for CWXY2 is at 1.8 of OD600 and the incubation time with lithium acetate is around 3 h.
The interaction mating assay
We used two mating assays in this study. In Figure 2c , we mated EGY48 containing an integrated LexAop-LEU2 reporter and pEG202-RasV 12 or RasA 15 with RFY206 containing peptide aptamers according to the previous protocol (Finley and Brent, 1994) . The specificity of these peptide aptamers were judged by cell growth in media lacking leucine. For the semi-quantitative mating assay in Figure 3 , we mated strain CWXY2, containing an integrated TetOp-URA3, TetR fusions of RasV 12 A 186 and RasA 186 with RFY206 expressing various peptide aptamers. We replicated the diploid yeast onto the galactose or glucose media supplemented with 5 mg/ml 6-azauracil but lack of Leu, Trp and Ura. The plates were incubated at 308C, and the results were scored after 3 days and up to 9 days.
Ras/Raf in vitro disruption assay
We purified recombinant GST-RasV 12 from bacteria and charged the protein with either GDP or GTP g S using standard protocols (10). We translated 35 S-labeled c-Raf1 (1 -330 residues) using a coupled transcription/translation system (Promega), and dialyzed the products against PBS for 2 h. We inserted DNA encoding peptide aptamers and thioredoxin into pMAL-c2 (New England Biolabs), expressed the maltose binding protein (MBP) fusions, and purified them using an amylose resin according to the manufacturer's instructions. For the disruption assays, we mixed the following components in 100 ml of binding buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 0.1% bovine serum albumin, 5 mM MgCl 2 , 1 mM DTT) and incubated the reaction for 1 h at 48C: GST agarose beads (Pharmacia) (30 ml of a 50% Two days after transfection, cells were starved with 0.1% fetal bovine serum for 16 h and then stimulated with hEGF (50 ng/ml) for 15 min. Cells were lyzed and immunoprecipitated for Myctagged c-Raf1. c-Raf1 kinase activity were assayed by sequential addition of recombinant MEK and kinase-dead Erk2 (Luo et al., 1996) . (c) Levels of immunoprecipitated Myc-tagged c-Raf1 in the kinase assay. (d) Expression levels of peptide aptamers and a Ras binding fragment of c-Raf1 (C4). Equal amount of total cellular proteins was separated on a SDS -PAGE and probed with anti-GST antibodies slurry), variable amounts of MBP aptamer fusions (1, 0.5, 0.1 mM), GST-RasV 12 (50 ng) and c-Raf1 (7 ml of in vitro translated mixture). We subsequently washed the GST agarose beads with the binding buffer containing 0.05% Triton and eluted GST RasV 12 with glutathione. We ran samples on 12% SDS -PAGE gels and exposed the gels to a phosphorimager plate.
Raf kinase assay
We tagged c-Raf1 protein with a Myc epitope (Luo et al., 1996) on its amino terminus and expressed if from the pMT2 plasmid. We cloned DNA encoding peptide aptamers into mammalian expression plasmid pEBG as GST fusions (Luo et al., 1996) . To assess the inhibitory effect of peptide aptamer on Ras signaling pathway, we cotransfected COS-1 cells with 1 mg of pMT2-c-Raf1 and 5 mg or pEBG-aptamer. After 2 days of incubation, we starved cells in a medium containing 0.1% fetal bovine serum for 16 h, and then stimulated cells with hEGF (50 ng/ml) for 15 min. We collected cells for lysis and immunoprecipitated the Myctagged c-Raf1 with anti-myc antibodies. We analysed c-Raf1 kinase activity using a coupled kinase assay in which recombinant MEK and kinase-dead Erk-2 were sequentially added to Raf immunoprecipitates in the presence of [ 32 P]-ATP (10). For Western blotting of c-Raf1, we used anti-Myc and GST antibodies to analyse the amount of c-Raf1 present in immunoprecipitates used in the kinase assays and expression levels of GST-peptide aptamers.
